Vosevi

Chemical Namesofosbuvir, velpatasvir and voxilaprevir
Dosage FormTablet (oral; 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir)
Drug ClassAntivirals
SystemDigestive
CompanyGilead Sciences Inc.
Approval Year2017

Indication

  • Indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: o Genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. o Genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vosevi (sofosbuvir, velpatasvir and voxilaprevir) Prescribing Information 2019Gilead Sciences, Inc., Foster City, CA